Identification

Name
Phenoxybenzamine
Accession Number
DB00925  (APRD00651)
Type
Small Molecule
Groups
Approved
Description

An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. [PubChem]

Structure
Thumb
Synonyms
  • Fenossibenzamina
  • Fenoxibenzamina
  • Phenoxybenzamine
  • Phenoxybenzaminum
  • POB
Product Ingredients
IngredientUNIICASInChI Key
Phenoxybenzamine HydrochlorideX1IEG24OHL63-92-3VBCPVIWPDJVHAN-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DibenzylineCapsule10 mg/1OralWell Spring Pharmaceutical Corporation1999-10-012017-10-31Us
DibenzylineCapsule10 mg/1OralConcordia Pharmaceuticals, Inc1953-01-26Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenoxybenzamine HydrochlorideCapsule10 mg/1OralPrasco, Laboratories2015-08-11Not applicableUs
Phenoxybenzamine HydrochlorideCapsule10 mg/1OralWest Ward Pharmaceutical2015-08-10Not applicableUs
Phenoxybenzamine HydrochlorideCapsule10 mg/1OralPar Pharmaceutical2017-01-24Not applicableUs
International/Other Brands
Dibenzyline
Categories
UNII
0TTZ664R7Z
CAS number
59-96-1
Weight
Average: 303.826
Monoisotopic: 303.138992038
Chemical Formula
C18H22ClNO
InChI Key
QZVCTJOXCFMACW-UHFFFAOYSA-N
InChI
InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
IUPAC Name
benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine
SMILES
CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1

Pharmacology

Indication

For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.

Associated Conditions
Pharmacodynamics

Phenoxybenzamine is indicated for the control of episodes of hypertension and sweating that occur with a disease called pheochromocytoma. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly. Phenoxybenzamine is a long-acting, adrenergic, alpha-receptor blocking agent which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Phenoxybenzamine works by blocking alpha receptors in certain parts of the body. Alpha receptors are present in the muscle that lines the walls of blood vessels. When the receptors are blocked by Phenoxybenzamine, the muscle relaxes and the blood vessels widen. This widening of the blood vessels results in a lowering of blood pressure.

Mechanism of action

Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UCalmodulin
inhibitor
Human
UBeta-2 adrenergic receptorNot AvailableHuman
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption

Twenty to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

24 hours

Clearance
Not Available
Toxicity

Symptoms of overdose are largely the result of block of the sympathetic nervous system and of the circulating epinephrine. They may include postural hypotension resulting in dizziness or fainting, tachycardia, particularly postural, vomiting; lethargy, and shock.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetaminePhenoxybenzamine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Phenoxybenzamine.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazinePhenoxybenzamine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
Acetyl sulfisoxazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdrafinilPhenoxybenzamine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatinePhenoxybenzamine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
AliskirenPhenoxybenzamine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Withdrawn
AmbrisentanPhenoxybenzamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronPhenoxybenzamine may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostinePhenoxybenzamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone.Approved, Investigational
AmitrazPhenoxybenzamine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylinePhenoxybenzamine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Phenoxybenzamine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved, Illicit
AmoxapinePhenoxybenzamine may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Phenoxybenzamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Amyl Nitrite.Approved
AnisodaminePhenoxybenzamine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Phenoxybenzamine can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Aranidipine.Approved, Investigational
ArbutaminePhenoxybenzamine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolPhenoxybenzamine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenoxybenzamine.Approved, Investigational
AsenapinePhenoxybenzamine may increase the antihypertensive activities of Asenapine.Approved
AtazanavirThe metabolism of Phenoxybenzamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
AtomoxetineThe metabolism of Phenoxybenzamine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Phenoxybenzamine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Azimilide.Investigational
BambuterolPhenoxybenzamine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Phenoxybenzamine.Experimental
BarbitalBarbital may increase the hypotensive activities of Phenoxybenzamine.Illicit
BarnidipinePhenoxybenzamine may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Bencyclane.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
BenidipineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
BenzphetaminePhenoxybenzamine may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilPhenoxybenzamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Phenoxybenzamine.Approved
BevantololPhenoxybenzamine may increase the antihypertensive activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Phenoxybenzamine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
BitolterolPhenoxybenzamine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe metabolism of Phenoxybenzamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
BortezomibThe metabolism of Phenoxybenzamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Phenoxybenzamine may increase the hypotensive activities of BQ-123.Investigational
BretyliumPhenoxybenzamine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazolePhenoxybenzamine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Phenoxybenzamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Phenoxybenzamine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoxybenzamine.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Phenoxybenzamine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the antihypertensive activities of Phenoxybenzamine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxybenzamine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
CadralazineCadralazine may increase the hypotensive activities of Phenoxybenzamine.Experimental
CafedrinePhenoxybenzamine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.Approved
CandesartanPhenoxybenzamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Phenoxybenzamine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Phenoxybenzamine.Experimental
CaptoprilPhenoxybenzamine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Phenoxybenzamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenoxybenzamine.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Phenoxybenzamine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
CeritinibThe serum concentration of Phenoxybenzamine can be increased when it is combined with Ceritinib.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Phenoxybenzamine.Approved, Vet Approved
ChlorpromazinePhenoxybenzamine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Phenoxybenzamine.Approved
CicletaninePhenoxybenzamine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilPhenoxybenzamine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenoxybenzamine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Cinnarizine.Approved, Investigational
CirazolinePhenoxybenzamine may decrease the vasoconstricting activities of Cirazoline.Experimental
ClarithromycinThe metabolism of Phenoxybenzamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Phenoxybenzamine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolPhenoxybenzamine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Phenoxybenzamine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenoxybenzamine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Phenoxybenzamine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
ClotrimazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePhenoxybenzamine may increase the antihypertensive activities of Clozapine.Approved
CobicistatThe metabolism of Phenoxybenzamine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Phenoxybenzamine.Approved, Investigational
CrizotinibThe metabolism of Phenoxybenzamine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Phenoxybenzamine.Approved
CurcuminThe metabolism of Phenoxybenzamine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Cyclandelate.Approved
CyclopenthiazidePhenoxybenzamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
DabrafenibThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Phenoxybenzamine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Phenoxybenzamine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Darodipine.Experimental
DarunavirThe metabolism of Phenoxybenzamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
DeferasiroxThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilPhenoxybenzamine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Phenoxybenzamine can be decreased when combined with Delavirdine.Approved
DeserpidinePhenoxybenzamine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxybenzamine.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
DetomidinePhenoxybenzamine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetaminePhenoxybenzamine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Phenoxybenzamine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Diclofenamide.Approved, Investigational
DiethylnorsperminePhenoxybenzamine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
DihydroergotamineThe metabolism of Phenoxybenzamine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Phenoxybenzamine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dinutuximab.Approved, Investigational
DipivefrinPhenoxybenzamine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Phenoxybenzamine.Approved
DL-MethylephedrinePhenoxybenzamine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutaminePhenoxybenzamine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexaminePhenoxybenzamine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Phenoxybenzamine.Approved
DotarizineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Phenoxybenzamine.Approved
DoxepinPhenoxybenzamine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllinePhenoxybenzamine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Phenoxybenzamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaronePhenoxybenzamine may increase the antihypertensive activities of Dronedarone.Approved
DroperidolPhenoxybenzamine may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaPhenoxybenzamine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetinePhenoxybenzamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipinePhenoxybenzamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Phenoxybenzamine.Approved, Vet Approved
EnalaprilatPhenoxybenzamine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Phenoxybenzamine.Experimental
EnzalutamideThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Eperisone.Approved, Investigational
EphedraPhenoxybenzamine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrinePhenoxybenzamine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastinePhenoxybenzamine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrinePhenoxybenzamine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Eplerenone.Approved
EpoprostenolPhenoxybenzamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
ErgonovinePhenoxybenzamine may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotaminePhenoxybenzamine may decrease the vasoconstricting activities of Ergotamine.Approved
ErythromycinThe metabolism of Phenoxybenzamine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
EscitalopramPhenoxybenzamine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Etacrynic acid.Approved, Investigational
EtafedrinePhenoxybenzamine may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Ethosuximide.Approved
EtilefrinePhenoxybenzamine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidatePhenoxybenzamine may decrease the vasoconstricting activities of Etomidate.Approved
FelodipinePhenoxybenzamine may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fendiline.Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Phenoxybenzamine.Approved
FenoterolPhenoxybenzamine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidPhenoxybenzamine may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenoxybenzamine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fish oil.Approved, Nutraceutical
FluconazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Flunarizine.Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Phenoxybenzamine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Phenoxybenzamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolPhenoxybenzamine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Phenoxybenzamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Phenoxybenzamine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
FosphenytoinThe metabolism of Phenoxybenzamine can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Phenoxybenzamine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Gallopamil.Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Phenoxybenzamine.Approved
GuanazodinePhenoxybenzamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePhenoxybenzamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
GuanoclorPhenoxybenzamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPhenoxybenzamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPhenoxybenzamine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Phenoxybenzamine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Phenoxybenzamine.Experimental
HexamethoniumPhenoxybenzamine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
HexoprenalinePhenoxybenzamine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePhenoxybenzamine may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Phenoxybenzamine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Phenoxybenzamine.Approved
HydrochlorothiazidePhenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
IdelalisibThe metabolism of Phenoxybenzamine can be decreased when combined with Idelalisib.Approved
IloperidonePhenoxybenzamine may increase the antihypertensive activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenoxybenzamine.Approved, Investigational
ImatinibThe metabolism of Phenoxybenzamine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenoxybenzamine.Investigational
ImipraminePhenoxybenzamine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolPhenoxybenzamine may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideIndapamide may increase the hypotensive activities of Phenoxybenzamine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Withdrawn
IndinavirThe metabolism of Phenoxybenzamine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the antihypertensive activities of Phenoxybenzamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
IrbesartanPhenoxybenzamine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Phenoxybenzamine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Phenoxybenzamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Phenoxybenzamine.Approved
IsoetarinePhenoxybenzamine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Phenoxybenzamine.Approved, Vet Approved
IsometheptenePhenoxybenzamine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalinePhenoxybenzamine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Phenoxybenzamine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Phenoxybenzamine can be increased when it is combined with Ivacaftor.Approved
KetanserinKetanserin may increase the hypotensive activities of Phenoxybenzamine.Investigational
KetoconazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Phenoxybenzamine.Approved
LacidipinePhenoxybenzamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenoxybenzamine.Approved, Investigational
LevodopaPhenoxybenzamine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosalbutamolPhenoxybenzamine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Phenoxybenzamine.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Lidoflazine.Experimental
LinsidominePhenoxybenzamine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetaminePhenoxybenzamine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
LofexidinePhenoxybenzamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Loperamide.Approved
LopinavirThe metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Phenoxybenzamine can be increased when it is combined with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
LovastatinThe metabolism of Phenoxybenzamine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Phenoxybenzamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Phenoxybenzamine can be increased when combined with Lumacaftor.Approved
MacitentanPhenoxybenzamine may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipinePhenoxybenzamine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MedetomidinePhenoxybenzamine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Menthol.Approved
MephenterminePhenoxybenzamine may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
MetaraminolPhenoxybenzamine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetaminePhenoxybenzamine may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Phenoxybenzamine.Approved
MethoserpidinePhenoxybenzamine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazinePhenoxybenzamine may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxaminePhenoxybenzamine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenaminePhenoxybenzamine may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methyclothiazide.Approved
MethyldopaPhenoxybenzamine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
MetipranololPhenoxybenzamine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Phenoxybenzamine.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
MetyrosinePhenoxybenzamine may increase the hypotensive activities of Metyrosine.Approved
MibefradilPhenoxybenzamine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePhenoxybenzamine may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Phenoxybenzamine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Phenoxybenzamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MirabegronPhenoxybenzamine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Phenoxybenzamine.Investigational
MitotaneThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Phenoxybenzamine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxybenzamine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
MuzoliminePhenoxybenzamine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenoxybenzamine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
NaftopidilPhenoxybenzamine may increase the hypotensive activities of Naftopidil.Investigational
NaphazolinePhenoxybenzamine may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
NefazodonePhenoxybenzamine may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Phenoxybenzamine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Phenoxybenzamine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
NicardipinePhenoxybenzamine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Phenoxybenzamine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nifedipine.Approved
NiguldipinePhenoxybenzamine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Phenoxybenzamine can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Niludipine.Experimental
NilvadipinePhenoxybenzamine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Phenoxybenzamine.Approved
NitrendipinePhenoxybenzamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenoxybenzamine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nitrous acid.Approved, Investigational
NorepinephrinePhenoxybenzamine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrinePhenoxybenzamine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylinePhenoxybenzamine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinPhenoxybenzamine may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabPhenoxybenzamine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
OctopaminePhenoxybenzamine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapinePhenoxybenzamine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Phenoxybenzamine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
OlodaterolPhenoxybenzamine may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Phenoxybenzamine.Investigational
OrciprenalinePhenoxybenzamine may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Phenoxybenzamine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
OxyfedrinePhenoxybenzamine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolinePhenoxybenzamine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenoxybenzamine.Approved, Vet Approved
PalbociclibThe serum concentration of Phenoxybenzamine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePhenoxybenzamine may increase the antihypertensive activities of Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Phenoxybenzamine.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
PentobarbitalThe metabolism of Phenoxybenzamine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPhenoxybenzamine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
PergolidePhenoxybenzamine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhendimetrazinePhenoxybenzamine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Phenoxybenzamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
PhenobarbitalThe metabolism of Phenoxybenzamine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
PhentolaminePhenoxybenzamine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrinePhenoxybenzamine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePhenoxybenzamine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Phenoxybenzamine can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Phenoxybenzamine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pipamperone.Approved, Investigational
PirbuterolPhenoxybenzamine may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Phenoxybenzamine.Approved
PitolisantThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
PizotifenPhenoxybenzamine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
PolythiazidePhenoxybenzamine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Phenoxybenzamine.Approved
PrenalterolPhenoxybenzamine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Phenoxybenzamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
ProcaterolPhenoxybenzamine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazinePhenoxybenzamine may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PropericiazinePhenoxybenzamine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePhenoxybenzamine may increase the antihypertensive activities of Propiomazine.Approved
PropiverinePhenoxybenzamine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved, Investigational
ProtokylolPhenoxybenzamine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrinePhenoxybenzamine may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapinePhenoxybenzamine may increase the antihypertensive activities of Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
QuinidinePhenoxybenzamine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Phenoxybenzamine.Approved
RacepinephrinePhenoxybenzamine may increase the antihypertensive activities of Racepinephrine.Approved
RactopaminePhenoxybenzamine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilRamipril may increase the hypotensive activities of Phenoxybenzamine.Approved
RanolazineThe metabolism of Phenoxybenzamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Phenoxybenzamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Phenoxybenzamine.Approved
ReproterolPhenoxybenzamine may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnaminePhenoxybenzamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
RifabutinThe metabolism of Phenoxybenzamine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Phenoxybenzamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Phenoxybenzamine can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
RimiterolPhenoxybenzamine may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatPhenoxybenzamine may increase the hypotensive activities of Riociguat.Approved
RisperidonePhenoxybenzamine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronPhenoxybenzamine may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrinePhenoxybenzamine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabPhenoxybenzamine may increase the hypotensive activities of Rituximab.Approved
RomifidinePhenoxybenzamine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Rotigotine.Approved
RucaparibThe metabolism of Phenoxybenzamine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Phenoxybenzamine.Withdrawn
SalbutamolPhenoxybenzamine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolPhenoxybenzamine may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanPhenoxybenzamine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Phenoxybenzamine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Seletracetam.Investigational
SelexipagPhenoxybenzamine may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Phenoxybenzamine.Approved
SiltuximabThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Phenoxybenzamine can be increased when it is combined with Simeprevir.Approved
SitaxentanPhenoxybenzamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronPhenoxybenzamine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
SpiraprilPhenoxybenzamine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Phenoxybenzamine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Phenoxybenzamine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SynephrinePhenoxybenzamine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Phenoxybenzamine.Approved, Investigational
TelaprevirThe metabolism of Phenoxybenzamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Phenoxybenzamine can be decreased when combined with Telithromycin.Approved
TelmisartanPhenoxybenzamine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPhenoxybenzamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Phenoxybenzamine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
TerlipressinPhenoxybenzamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Experimental
TetrahydropalmatinePhenoxybenzamine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolinePhenoxybenzamine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalinePhenoxybenzamine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the hypotensive activities of Phenoxybenzamine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Phenoxybenzamine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Phenoxybenzamine.Approved, Vet Approved
ThioproperazinePhenoxybenzamine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Phenoxybenzamine.Approved, Withdrawn
TibolonePhenoxybenzamine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Phenoxybenzamine can be decreased when combined with Ticlopidine.Approved
TicrynafenPhenoxybenzamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the antihypertensive activities of Phenoxybenzamine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Tolfenamic Acid.Approved, Investigational
TolonidinePhenoxybenzamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Phenoxybenzamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Phenoxybenzamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Phenoxybenzamine.Approved
TranilastThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Phenoxybenzamine.Approved
TrazodonePhenoxybenzamine may increase the antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolPhenoxybenzamine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Triamterene.Approved
TrichlormethiazidePhenoxybenzamine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazinePhenoxybenzamine may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Phenoxybenzamine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
TrimipraminePhenoxybenzamine may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolPhenoxybenzamine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
UnoprostonePhenoxybenzamine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Phenoxybenzamine.Investigational
ValsartanValsartan may increase the hypotensive activities of Phenoxybenzamine.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Phenoxybenzamine.Approved
VemurafenibThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Phenoxybenzamine can be decreased when combined with Venlafaxine.Approved
VerapamilPhenoxybenzamine may increase the antihypertensive activities of Verapamil.Approved
VilanterolPhenoxybenzamine may decrease the vasoconstricting activities of Vilanterol.Approved
VincaminePhenoxybenzamine may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePhenoxybenzamine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Phenoxybenzamine can be decreased when combined with Voriconazole.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with WIN 55212-2.Experimental
XamoterolPhenoxybenzamine may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamidePhenoxybenzamine may increase the hypotensive activities of Xipamide.Experimental
XylazinePhenoxybenzamine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolinePhenoxybenzamine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Phenoxybenzamine.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Phenoxybenzamine.Approved
ZofenoprilPhenoxybenzamine may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolPhenoxybenzamine may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551-4. [PubMed:88984]
  2. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
External Links
Human Metabolome Database
HMDB0015061
KEGG Compound
C07435
PubChem Compound
4768
PubChem Substance
46507191
ChemSpider
4604
BindingDB
50017679
ChEBI
8077
ChEMBL
CHEMBL753
Therapeutic Targets Database
DAP000478
PharmGKB
PA450919
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Phenoxybenzamine
ATC Codes
C04AX02 — Phenoxybenzamine
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCardiopulmonary Bypass / Open-heart Surgery1
2Unknown StatusTreatmentCongenital Heart Disease (CHD)1
3RecruitingTreatmentParaganglioma / Pheochromocytomas1
4CompletedTreatmentPheochromocytomas1
Not AvailableTerminatedTreatmentCardiopulmonary Bypass / Congenital Heart Surgery1

Pharmacoeconomics

Manufacturers
  • Wellspring pharmaceutical corp
Packagers
  • Gallipot
  • Murfreesboro Pharmaceutical Nursing Supply
  • Wellspring Pharmaceutical
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
Prices
Unit descriptionCostUnit
Phenoxybenzamine hcl powd42.35USD g
Dibenzyline 10 mg capsule8.61USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)39 °CPhysProp
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0103 mg/mLALOGPS
logP4.26ALOGPS
logP4.64ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)7.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity88.92 m3·mol-1ChemAxon
Polarizability34.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9629
Caco-2 permeable+0.7367
P-glycoprotein substrateSubstrate0.6059
P-glycoprotein inhibitor IInhibitor0.6043
P-glycoprotein inhibitor IIInhibitor0.5871
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.6666
CYP450 2D6 substrateNon-substrate0.6013
CYP450 3A4 substrateSubstrate0.5937
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.7714
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6682
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7565
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity2.1163 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7145
hERG inhibition (predictor II)Inhibitor0.5874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylmethylamines
Alternative Parents
Phenoxy compounds / Phenol ethers / Benzylamines / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
Substituents
Benzylamine / Phenoxy compound / Phenol ether / Phenylmethylamine / Alkyl aryl ether / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Ether / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic amine (CHEBI:8077)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Stam WB, Van der Graaf PH, Saxena PR: Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol. 1999 Jun;127(3):661-70. [PubMed:10401556]
  2. Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719]
  3. Yu Y, Koss MC: Functional characterization of alpha-adrenoceptors mediating pupillary dilation in rats. Eur J Pharmacol. 2003 Jun 20;471(2):135-40. [PubMed:12818701]
  4. Salles J, Gascon S, Badia A: Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):408-16. [PubMed:8935707]
  5. Suzuki E, Tsujimoto G, Tamura K, Hashimoto K: Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role. Mol Pharmacol. 1990 Nov;38(5):725-36. [PubMed:1978244]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Cimino M, Weiss B: Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem Pharmacol. 1988 Jul 15;37(14):2739-45. [PubMed:3134891]
  2. Suko J, Wyskovsky W, Pidlich J, Hauptner R, Plank B, Hellmann G: Calcium release from calmodulin and its C-terminal or N-terminal halves in the presence of the calmodulin antagonists phenoxybenzamine and melittin measured by stopped-flow fluorescence with Quin 2 and intrinsic tyrosine. Inhibition of calmodulin-dependent protein kinase of cardiac sarcoplasmic reticulum. Eur J Biochem. 1986 Sep 15;159(3):425-34. [PubMed:3758070]
  3. Lukas TJ, Marshak DR, Watterson DM: Drug-protein interactions: isolation and characterization of covalent adducts of phenoxybenzamine and calmodulin. Biochemistry. 1985 Jan 1;24(1):151-7. [PubMed:3994963]
  4. Earl CQ, Prozialeck WC, Weiss B: Interaction of alpha adrenergic antagonists with calmodulin. Life Sci. 1984 Jul 30;35(5):525-34. [PubMed:6146911]
  5. Kuromi H, Yoshihara M, Kidokoro Y: An inhibitory role of calcineurin in endocytosis of synaptic vesicles at nerve terminals of Drosophila larvae. Neurosci Res. 1997 Feb;27(2):101-13. [PubMed:9100252]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA: Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. [PubMed:7969082]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA: Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. [PubMed:7969082]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:35